Truist Ignites Excitement for Rapport Therapeutics (RAPP) with New 'Buy' Rating and $21 Price Target
Brixmor Property Group Under the Microscope: Decoding Analyst Sentiments
Digital Realty Trust: Unpacking Analyst Views on a Data Center Giant